WALTHAM, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive breast cancers, announced today that it will host its first Investor Day on Tuesday, November 17 from 8:00 a.m. to 11:30 a.m. EST in New York City.
A live webcast of the presentations will be available from the "Events & Presentations" page of Radius’ website at http://ir.radiuspharm.com/events.cfm. A replay will also be available approximately two hours after completion of the event and will be archived on the Company's website.
Date: November 17, 2015
Time: 8:00 a.m. – 11:30 a.m. EST
Breakfast and Registration: 8:00 a.m. – 8:30 a.m. EST
Program and Webcast: 8:30 a.m. – 11:30 a.m. EST
Robert E. Ward: President and Chief Executive Officer
Gary Hattersley: Chief Scientific Officer
Lorraine Fitzpatrick: Chief Medical Officer
Dinesh Purandare: SVP, Global Head of Oncology
Greg Williams: Chief Development Officer
David Snow: Chief Commercial Officer
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, and vasomotor symptoms. www.radiuspharm.com